Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma

Journal of Controlled Release

Volumn 225, Issue , 2016, Pages 283-293

  Bastiancich, C ^a   Vanvarenberg, K ^a   Ucakar, B ^a   Pitorre, M ^b   Bastiat, G ^b   Lagarce, F ^b   Preat V ^a   Danhier, F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Gemcitabine; Glioblastoma; Hydrogel; Lipid nanocapsules; Nanomedicine

Indexed keywords

CYTOTOXICITY; MEDICAL NANOTECHNOLOGY; NANOCAPSULES; TUMORS; VISCOELASTICITY;

CHEMOTHERAPEUTIC AGENTS; DIFFERENT MECHANISMS; GEMCITABINE; GLIOBLASTOMAS; LIPID NANOCAPSULES; NANO-DELIVERY SYSTEMS; SAFETY AND EFFICIENCIES; VISCOELASTIC PROPERTIES;

HYDROGELS;

GEMCITABINE; LIPID; NANOCAPSULE; ANTINEOPLASTIC ANTIMETABOLITE; DELAYED RELEASE FORMULATION; DEOXYCYTIDINE; HYDROGEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYDROGEL; HYDROPHILICITY; IN VITRO STUDY; LOCAL THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FLOW KINETICS; INJECTION; NEEDLE; NUDE MOUSE; PATHOLOGY; THERAPEUTIC USE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DEOXYCYTIDINE; DRUG LIBERATION; FEMALE; GLIOBLASTOMA; HUMANS; HYDROGELS; INJECTIONS; LIPIDS; MICE, NUDE; NANOCAPSULES; NEEDLES; RHEOLOGY; TUMOR BURDEN;

EID: 84959420600     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.054     Document Type: Article

References (76)

1. K.A. Batich, and J.H. Sampson Standard of care and future pharmacological treatment options for malignant glioma: An urgent need for screening and identification of novel tumor-specific antigens Expert. Opin. Pharmacother. 15 2014 2047 2061
2. S. Tsigkos, S. Mariz, J. Llinares, L. Fregonese, S. Aarum, N.W. Frauke, K. Westermark, and B. Sepodes Establishing medical plausibility in the context of orphan medicines designation in the European Union Orphanet J. Rare Dis. 9 2014 175
3. Q.T. Ostrom, H. Gittleman, P. Farah, A. Ondracek, Y. Chen, Y. Wolinsky, N.E. Stroup, C. Kruchko, and J.S. Barnholtz-Sloan CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro-Oncology 15 Suppl. 2 2013 ii1 i56
4. S.A. Grossman, X. Ye, S. Piantadosi, S. Desideri, L.B. Nabors, M. Rosenfeld, and J. Fisher Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States Clin. Cancer Res. 16 2010 2443 2449
5. R.D. Kortmann, B. Jeremic, M. Weller, L. Plasswilm, and M. Bamberg Radiochemotherapy of malignant glioma in adults. clinical experiences Strahlenther. Onkol. 179 2003 219 232
6. R. Stupp, M. Brada, M.J. van den Bent, J.C. Tonn, and G. Pentheroudakis High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 25 Suppl. 3 2014 iii93 ii101
7. P.P. Wang, J. Frazier, and H. Brem Local drug delivery to the brain Adv. Drug Deliv. Rev. 54 2002 987 1013
8. S.A. Grossman, and J.F. Batara Current management of glioblastoma multiforme Semin. Oncol. 31 2004 635 644
9. Q. Pan, X.J. Yang, H.M. Wang, X.T. Dong, W. Wang, Y. Li, and J.M. Li Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen Cell Biochem. Biophys. 62 2012 185 191
10. J.N. Sarkaria, G.J. Kitange, C.D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of chemoresistance to alkylating agents in malignant glioma Clin. Cancer Res. 14 2008 2900 2908
11. F. Danhier, K. Messaoudi, L. Lemaire, J.P. Benoit, and F. Lagarce Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation Int. J. Pharm. 481 2015 154 161
12. K. Messaoudi, A. Clavreul, and F. Lagarce Toward an effective strategy in glioblastoma treatment. Part I: Resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide Drug Discov. Today 20 2015 899 905
13. F. Danhier, O. Feron, and V. Preát To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
14. F. Danhier, A. Le Breton, and V. Preát RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis Mol. Pharm. 9 2012 2961 2973
15. N.T. Huynh, C. Passirani, P. Saulnier, and J.P. Benoit Lipid nanocapsules: A new platform for nanomedicine Int. J. Pharm. 379 2009 201 209
16. J. Aparicio-Blanco, and A.I. Torres-Suarez Glioblastoma multiforme and lipid nanocapsules: A review J. Biomed. Nanotechnol. 11 2015 1283 1311
17. F.H. Hochberg, and A. Pruitt Assumptions in the radiotherapy of glioblastoma Neurology 30 1980 907 911
18. M. Westphal, D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, P.C. Warnke, I.R. Whittle, J. Jaaskelainen, and Z. Ram A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-Oncology 5 2003 79 88
19. H.H. Engelhard The role of interstitial BCNU chemotherapy in the treatment of malignant glioma Surg. Neurol. 53 2000 458 464
20. D.A. Bota, A. Desjardins, J.A. Quinn, M.L. Affronti, and H.S. Friedman Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas Ther. Clin. Risk Manag. 3 2007 707 715
21. T.A. Juratli, G. Schackert, and D. Krex Current status of local therapy in malignant gliomas-a clinical review of three selected approaches Pharmacol. Ther. 139 2013 341 358
22. S. Brem, B. Tyler, K. Li, G. Pradilla, F. Legnani, J. Caplan, and H. Brem Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model Cancer Chemother. Pharmacol. 60 2007 643 650
23. B. Tyler, K.D. Fowers, K.W. Li, V.R. Recinos, J.M. Caplan, A. Hdeib, R. Grossman, L. Basaldella, K. Bekelis, G. Pradilla, F. Legnani, and H. Brem A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats J. Neurosurg. 113 2010 210 217
24. T. Ozeki, D. Kaneko, K. Hashizawa, Y. Imai, T. Tagami, and H. Okada Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model Biol. Pharm. Bull. 35 2012 545 550
25. B.Y. Ong, S.H. Ranganath, L.Y. Lee, F. Lu, H.S. Lee, N.V. Sahinidis, and C.H. Wang Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme Biomaterials 30 2009 3189 3196
26. A.K. Vellimana, V.R. Recinos, L. Hwang, K.D. Fowers, K.W. Li, Y. Zhang, S. Okonma, C.G. Eberhart, H. Brem, and B.M. Tyler Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model J. Neuro-Oncol. 111 2013 229 236
27. P. Menei, L. Capelle, J. Guyotat, S. Fuentes, R. Assaker, B. Bataille, P. Francois, D. Dorwling-Carter, P. Paquis, L. Bauchet, F. Parker, J. Sabatier, N. Faisant, and J.P. Benoit Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: A randomized phase II trial Neurosurgery 56 2005 242 248 (discussion 242-248)
28. T. Fourniols, L.D. Randolph, A. Staub, K. Vanvarenberg, J.G. Leprince, V. Preat, A. des Rieux, and F. Danhier Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma J. Control. Release 210 2015 95 104
29. J. Sigmond, R.J. Honeywell, T.J. Postma, C.M. Dirven, S.M. de Lange, K. van der Born, A.C. Laan, J.C. Baayen, C.J. Van Groeningen, A.M. Bergman, G. Giaccone, and G.J. Peters Gemcitabine uptake in glioblastoma multiforme: Potential as a radiosensitizer Ann. Oncol. 20 2009 182 187
30. E. Moysan, G. Bastiat, and J.P. Benoit Gemcitabine versus modified gemcitabine: A review of several promising chemical modifications Mol. Pharm. 10 2013 430 444
31. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Control. Release 100 2004 331 346
32. E. Moysan, Y. Gonzalez-Fernandez, N. Lautram, J. Bejaud, G. Bastiat, and J.P. Benoit An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: When the drug is a key player of the nanomedicine structure Soft Matter 10 2014 1767 1777
33. S. Galban, B. Lemasson, T.M. Williams, F. Li, K.A. Heist, T.D. Johnson, J.S. Leopold, T.L. Chenevert, T.S. Lawrence, A. Rehemtulla, T. Mikkelsen, E.C. Holland, C.J. Galban, and B.D. Ross DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma PLoS One 7 2012 e35857
34. S.P., B. Heurtault, B. Pech, J.E. Proust, J. Richard, and J.P. Benoit Lipidic Nanocapsules, Formulation Process and Use as a Drug Delivery System 2001
35. B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, and J.P. Benoit A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 19 2002 875 880
36. S. Arpicco, C. Lerda, E. Dalla Pozza, C. Costanzo, N. Tsapis, B. Stella, M. Donadelli, I. Dando, E. Fattal, L. Cattel, and M. Palmieri Hyaluronic acid-coated liposomes for active targeting of gemcitabine Eur. J. Pharm. Biopharm. 85 2013 373 380
37. A. Beloqui, M.Á. Solinís, A.R. Gascón, A. del Pozo-Rodríguez, A. des Rieux, and V. Preát Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier J. Control. Release 166 2013 115 123
38. N. Hajos, and I. Mody Establishing a physiological environment for visualized in vitro brain slice recordings by increasing oxygen supply and modifying aCSF content J. Neurosci. Methods 183 2009 107 113
39. K.K. Chereddy, A. Lopes, S. Koussoroplis, V. Payen, C. Moia, H. Zhu, P. Sonveaux, P. Carmeliet, A. des rieux, G. Vandermeulen, and V. Preát Combined effects of PLGA and vascular endothelial growth factor promote the healing of non-diabetic and diabetic wounds Nanomedicine 11 2015 1975 1984
40. H. Meng, M. Wang, H. Liu, X. Liu, A. Situ, B. Wu, Z. Ji, C.H. Chang, and A.E. Nel Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice ACS Nano 9 2015 3540 3557
41. X. Yu, Y. Di, C. Xie, Y. Song, H. He, H. Li, X. Pu, W. Lu, D. Fu, and C. Jin An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line Int. J. Nanomedicine 10 2015 6825 6834
42. D. Cosco, D. Paolino, F. De Angelis, F. Cilurzo, C. Celia, L. Di Marzio, D. Russo, N. Tsapis, E. Fattal, and M. Fresta Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response Eur. J. Pharm. Biopharm. 89 2015 30 39
43. T. Manabe, H. Okino, R. Maeyama, K. Mizumoto, M. Tanaka, and T. Matsuda New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer J. Biomed. Mater. Res. B Appl. Biomater. 73 2005 203 207
44. S. Bobone, E. Miele, B. Cerroni, D. Roversi, A. Bocedi, E. Nicolai, A. Di Venere, E. Placidi, G. Ricci, N. Rosato, and L. Stella Liposome-templated hydrogel nanoparticles as vehicles for enzyme-based therapies Langmuir 31 2015 7572 7580
45. J. Hao, X. Wang, Y. Bi, Y. Teng, J. Wang, F. Li, Q. Li, J. Zhang, F. Guo, and J. Liu Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery Colloids Surf. B Biointerfaces 114 2014 111 120
46. A.C. Santos Akkari, E.V. Ramos Campos, A.F. Keppler, L.F. Fraceto, E. de Paula, G.R. Tofoli, and D.R. de Araujo Budesonide-hydroxypropyl-beta-cyclodextrin inclusion complex in binary poloxamer 407/403 system for ulcerative colitis treatment: A physico-chemical study from micelles to hydrogels Colloids Surf. B: Biointerfaces 138 2016 138 147
47. S. Chatelin, A. Constantinesco, and R. Willinger Fifty years of brain tissue mechanical testing: From in vitro to in vivo investigations Biorheology 47 2010 255 276
48. J.J. Iliff, M. Wang, Y. Liao, B.A. Plogg, W. Peng, G.A. Gundersen, H. Benveniste, G.E. Vates, R. Deane, S.A. Goldman, E.A. Nagelhus, and M. Nedergaard A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta Sci. Transl. Med. 4 2012 147ra111
49. P. Menei, E. Jadaud, N. Faisant, M. Boisdron-Celle, S. Michalak, D. Fournier, M. Delhaye, and J.P. Benoit Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma Cancer 100 2004 405 410
50. J. Rieger, S. Durka, J. Streffer, J. Dichgans, and M. Weller Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone Eur. J. Pharmacol. 365 1999 301 308
51. L.J. Ostruszka, and D.S. Shewach The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine Cancer Res. 60 2000 6080 6088
52. P. Guo, J. Ma, S. Li, Z. Guo, A.L. Adams, and J.M. Gallo Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model Cancer Chemother. Pharmacol. 48 2001 169 176
53. M. Genc, N. Castro Kreder, A. Barten-van Rijbroek, L.J. Stalpers, and J. Haveman Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids J. Cancer Res. Clin. Oncol. 130 2004 45 51
54. G. Carpinelli, B. Bucci, I. D'Agnano, R. Canese, F. Caroli, L. Raus, E. Brunetti, D. Giannarelli, F. Podo, and C.M. Carapella Gemcitabine treatment of experimental C6 glioma: The effects on cell cycle and apoptotic rate Anticancer Res. 26 2006 3017 3024
55. C.X. Wang, L.S. Huang, L.B. Hou, L. Jiang, Z.T. Yan, Y.L. Wang, and Z.L. Chen Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model Brain Res. 1261 2009 91 99
56. P. Brusa, M.L. Immordino, F. Rocco, and L. Cattel Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs Anticancer Res. 27 2007 195 199
57. W.G. Chung, M.A. Sandoval, B.R. Sloat, P.D. Lansakara, and Z. Cui Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1 J. Control. Release 157 2012 132 140
58. B.R. Sloat, M.A. Sandoval, D. Li, W.G. Chung, P.D. Lansakara, P.J. Proteau, K. Kiguchi, J. DiGiovanni, and Z. Cui In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 409 2011 278 288
59. N. Wauthoz, G. Bastiat, E. Moysan, A. Cieslak, K. Kondo, M. Zandecki, V. Moal, M.C. Rousselet, J. Hureaux, and J.P. Benoit Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice Nanomedicine 11 2015 1237 1245
60. E. Garcion, A. Lamprecht, B. Heurtault, A. Paillard, A. Aubert-Pouessel, B. Denizot, P. Menei, and J.P. Benoit A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats Mol. Cancer Ther. 5 2006 1710 1722
61. A. Paillard, F. Hindre, C. Vignes-Colombeix, J.P. Benoit, and E. Garcion The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability Biomaterials 31 2010 7542 7554
62. H. Okino, R. Maeyama, T. Manabe, T. Matsuda, and M. Tanaka Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice Clin. Cancer Res. 9 2003 5786 5793
63. O. Benny, S.K. Kim, K. Gvili, I.S. Radzishevsky, A. Mor, L. Verduzco, L.G. Menon, P.M. Black, M. Machluf, and R.S. Carroll In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model FASEB J. 22 2008 488 499
64. J.T. Dilworth, S.A. Krueger, M. Dabjan, I.S. Grills, J. Torma, G.D. Wilson, and B. Marples Pulsed low-dose irradiation of orthotopic glioblastoma multiforme (GBM) in a pre-clinical model: Effects on vascularization and tumor control Radiother. Oncol. 108 2013 149 154
65. Q. Mu, G. Lin, V.K. Patton, K. Wang, O.W. Press, and M. Zhang Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy J. Mater. Chem. B 4 2016 32 36
66. D.H. Shin, S.J. Lee, J.S. Kim, J.H. Ryu, and J.S. Kim Synergistic effect of immunoliposomal gemcitabine and bevacizumab in glioblastoma stem cell-targeted therapy J. Biomed. Nanotechnol. 11 2015 1989 2002
67. S.Z. Gertler, D. MacDonald, M. Goodyear, P. Forsyth, D.J. Stewart, K. Belanger, J. Perry, D. Fulton, W. Steward, N. Wainman, and L. Seymour NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94) Ann. Oncol. 11 2000 315 318
68. M. Weller, J. Streffer, W. Wick, R.D. Kortmann, E. Heiss, W. Kuker, R. Meyermann, J. Dichgans, and M. Bamberg Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study Cancer 91 2001 423 427
69. A. Fabi, A. Mirri, A. Felici, A. Vidiri, A. Pace, E. Occhipinti, F. Cognetti, G. Arcangeli, B. Iandolo, M.A. Carosi, G. Metro, and C.M. Carapella Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: A dose-finding study J. Neuro-Oncol. 87 2008 79 84
70. G. Metro, A. Fabi, M.A. Mirri, A. Vidiri, A. Pace, M. Carosi, M. Russillo, M. Maschio, D. Giannarelli, D. Pellegrini, A. Pompili, F. Cognetti, and C.M. Carapella Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme Cancer Chemother. Pharmacol. 65 2010 391 397
71. W. Wick, M. Hermisson, R.D. Kortmann, W.M. Kuker, F. Duffner, J. Dichgans, M. Bamberg, and M. Weller Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: A phase II study J. Neuro-Oncol. 59 2002 151 155
72. Shimizu Routes of administration H.J. Hedrich, The Laboratory Mouse (Handbook of Experimental Animals) 2004 Elsevier 527 541
73. E. Fournier, C. Passirani, C.N. Montero-Menei, and J.P. Benoit Biocompatibility of implantable synthetic polymeric drug carriers: Focus on brain biocompatibility Biomaterials 24 2003 3311 3331
74. D. Ito, Y. Imai, K. Ohsawa, K. Nakajima, Y. Fukuuchi, and S. Kohsaka Microglia-specific localisation of a novel calcium binding protein, Iba1 Brain Res. Mol. Brain Res. 57 1998 1 9
75. K.B. Bjugstad, K. Lampe, D.S. Kern, and M. Mahoney Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: An analysis of the glial response across space and time J. Biomed. Mater. Res. A 95 2010 79 91
76. M.T. Giordana, A. Attanasio, P. Cavalla, A. Migheli, M.C. Vigliani, and D. Schiffer Reactive cell proliferation and microglia following injury to the rat brain Neuropathol. Appl. Neurobiol. 20 1994 163 174